SPRIX: payments to doctors
Payments that named SPRIX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $298K
- Providers
- 5,874
- Transactions
- 25,223
- Average per transaction
- $12
The per-transaction average — $12 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,874 providers the average total is $51, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Zyla Life Sciences | $154,072 | 51.7% |
| Zyla Life Sciences, Inc. | $95,874 | 32.2% |
| Assertio Therapeutics, Inc. | $41,580 | 13.9% |
| Orapharma, A Division Of Bausch Health US, LLC | $3,353 | 1.1% |
| Ascend Therapeutics US, LLC | $3,145 | 1.1% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $128 | 0.0% |
| Bausch & Lomb Americas Inc. | $28 | 0.0% |